Discovery and development of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as Bcl-2/Mcl-1 inhibitors
Authors:
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 88, 102938
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 18 references indexed in Scilit:
- Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitorsBioorganic & Medicinal Chemistry, 2015
- Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL‐2 family membersThe FEBS Journal, 2015
- The BCL-2 protein family, BH3-mimetics and cancer therapyCell Death & Differentiation, 2015
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer TherapeuticsCancer Discovery, 2015
- Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of plateletsBlood, 2011
- Discovery of a Tetrahydroisoquinoline-Based Hydroxamic Acid Derivative (ZYJ-34c) as Histone Deacetylase Inhibitor with Potent Oral Antitumor ActivitiesJournal of Medicinal Chemistry, 2011
- Discovery and Development of Thiazolo[3,2‐a]pyrimidinone Derivatives as General Inhibitors of Bcl‐2 Family ProteinsChemMedChem, 2011
- Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitorsBioorganic & Medicinal Chemistry, 2010
- An Improved Synthesis of (3R)-2-(tert-Butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic AcidSynthesis, 2008
- Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarizationAnalytical Biochemistry, 2004